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Iron deficiency anaemia is a global health concern
affecting children, women and the elderly, whilst
also being a common comorbidity in multiple
medical conditions. The aetiology is variable and
attributed to several risk factors decreasing iron
intake and absorption or increasing demand and
loss, with multiple aetiologies often coexisting in an
individual patient. Although presenting symptoms
may be nonspecific, there is emerging evidence on
the detrimental effects of iron deficiency anaemia
on clinical outcomes across several medical
conditions. Increased awareness about the conse-
quences and prevalence of iron deficiency anaemia
can aid early detection and management. Diagno-
sis can be easily made by measurement of haemo-
globin and serum ferritin levels, whilst in chronic
inflammatory conditions, diagnosis may be more
challenging and necessitates consideration of
higher serum ferritin thresholds and evaluation of
transferrin saturation. Oral and intravenous for-
mulations of iron supplementation are available,
and several patient and disease-related factors
need to be considered before management deci-
sions are made. This review provides recent
updates and guidance on the diagnosis and man-
agement of iron deficiency anaemia in multiple
clinical settings.
Keywords: anaemia, complications, diagnosis, iron
deficiency, management, pathophysiology.
Introduction
Iron deficiency anaemia (IDA) remains amongst
the five leading causes of years lived with
disability in humans, and the top cause in
women [1]. Although it has been mainly regarded
as a public health concern affecting growing
children, premenopausal and pregnant women,
it is also being increasingly recognized as a
clinical condition that can affect patients pre-
senting to various medical and surgical spe-
cialties, especially those with chronic conditions
and the elderly. Emerging evidence on the role of
IDA in worsening clinical outcomes continues to
accumulate, which prompted careful considera-
tion of IDA diagnosis and management in inter-
national practice guidelines. The multiple
aetiologies of IDA and nonspecificity of symp-
toms, however, can challenge the diagnosis.
Moreover, the availability of different formula-
tions of iron supplementation can complicate
treatment decisions. These aspects are discussed
in this Review using the best available evidence
and experience of the authors.
Aetiology
There are multiple physiologic, environmental,
pathologic and genetic causes of iron deficiency
(ID) that lead to IDA (Fig. 1). More importantly,
aetiologies may vary considerably or tend to coexist
in different patient populations (children, women
and elderly), geographies (developing and devel-
oped countries) and specific clinical conditions.
There is also a considerable complexity and a large
repository of terminology for various subtypes of ID
which are commonly used interchangeably or in
contradiction in the literature.
Absolute iron deficiency anaemia
‘Absolute ID’ refers to the reduction of total body
iron stores (mostly in macrophages and hepato-
cytes) which may or may not progress in severity
leading to IDA [2]. Absolute ID may occur in
instances of increased demand, decreased intake,
decreased or malabsorption, or chronic blood loss.
Increased demand is usually physiologic and com-
monly noted in infants, preschool children, growth
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spurts in adolescents and pregnancy (mostly sec-
ond and third trimesters) [2–4]. Decreased iron
intake can be a direct consequence of poverty and
malnutrition as the case with many children and
pregnant women in developing countries or attrib-
uted to iron-poor vegan or vegetarian diets [2–4].
Decreased absorption is recognized in certain
dietary practices, with several inhibitors of iron
absorption recognized such as calcium, phytates
(present in cereals) and tannins (present in tea and
coffee) [5]. It is also attributed to surgical proce-
dures including gastrectomy, duodenal bypass and
bariatric surgery (especially Roux-en-Y gastric
bypass) which increase stomach pH and decrease
conversion to ferrous iron. Certain medical condi-
tions are also known to be associated with
decreased iron absorption such as infection with
Helicobacter pylori (competition for iron, increased
PH and reduction of vitamin C), coeliac disease
(gluten-induced enteropathy), atrophic gastritis
(increased PH) and inflammatory bowel disease
[2–4, 6, 7]. It should be noted that such conditions
of decreased iron absorption, in most instances,
render patients refractory to oral iron therapy [8].
The use of proton-pump inhibitors may also con-
tribute to decreased iron absorption [9].
Chronic blood loss can be physiologic as in men-
struating women. Frequent blood donors are also
known to develop ID [2, 10]. In developing coun-
tries, hookworm and schistosomiasis infections are
very common causes of chronic gastrointestinal or
systemic blood loss, respectively [11]. In more
developed countries, chronic blood loss is mostly
observed in women with heavy menstrual bleeding
or in men and elderly patients with chronic blood
loss from the gastrointestinal tract [2–4]. Chronic
blood loss is also implicated in patients on dialysis.
Other rare causes could include intravascular
haemolysis leading to urinary bleeding or other
systemic sources of chronic bleeding [2–4]. The use
of salicylates, nonsteroidal anti-inflammatory
drugs, anticoagulants and corticosteroids may also
result in drug-induced blood loss due to direct
irritation of the gastric mucosa or the tendency of
Fig. 1 Various aetiologies of iron deficiency anaemia. CHF, chronic heart failure; CKD, chronic kidney disease; CPD, chronic
pulmonary disease; ESA, erythropoiesis-stimulating agents; IBD, inflammatory bowel disease; ID, iron deficiency; IRIDA,
iron-refractory iron deficiency anaemia; NSAIDs, Nonsteroidal anti-inflammatory drugs; PNH, paroxysmal nocturnal
haemoglobinuria; PPI, proton-pump inhibitors.
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these agents to increase bleeding risk from other
causes [2, 4].
Functional iron deficiency anaemia
‘Functional’ or ‘relative’ ID (and subsequent IDA)
is a term used in the literature to describe two
main scenarios: (i) situations when iron is hardly
mobilized from stores to the circulation and
erythropoietic tissue in view of chronic inflamma-
tion and elevated hepcidin levels, such as in
patients with chronic kidney disease, chronic
heart failure, inflammatory bowel disease, chronic
pulmonary diseases, cancer, obesity, other
autoimmune diseases and chronic infections [4].
Absolute ID may manifest in later stages in view
of decreased iron absorption signalled by high
hepcidin levels [3]. (ii) Situations of increased
erythropoiesis mediated either by endogenous
erythropoietin responses to anaemia or by ther-
apy with erythropoiesis-stimulating agents (ESA)
creating a mismatch between iron demand and
supply [2, 4, 12]. It is also common to call
erythropoiesis in these instances as iron-re-
stricted or iron-poor erythropoiesis [2, 12]. From
a diagnostic standpoint, it is essential to realize
that indices of iron stores could be normal or
high in these scenarios [13].
Iron-refractory iron deficiency anaemia
Genetic causes of IDA exist. Iron-refractory IDA
(IRIDA) is a rare recessive condition caused by a
mutation in TMPRSS6 leading to elevated hepcidin
levels and decreased intestinal iron absorption, a
situation similar to the effects of chronic inflam-
mation [14, 15]. IRIDA patients are particularly
refractory to oral iron supplementation (as well to
ESA therapy) [8]. Anaemia in IRIDA is usually less
severe in adults than in children [16].
Table 1 highlights patient populations and specific
clinical conditions for which multiple aetiologies of
IDA are commonly observed including children in
developing countries, endurance athletes, the
elderly, chronic kidney disease, chronic heart fail-
ure, obesity, inflammatory bowel disease and fol-
lowing major surgery [2, 4, 6, 17–31]. Other
nutritional anaemias (folate or vitamin B12 defi-
ciency) may also coexist with IDA, especially in the
elderly, children in developing countries or patients
with gastrointestinal disorders. Decreased levels of
erythropoietin are also reported in elderly patients
who may have anaemia in the absence of ID.
Table 1. Examples of populations and clinical conditions





• Decreased intake (malnutrition)
• Chronic gastrointestinal blood loss
(parasitic infections)
• Decreased absorption (parasitic
infections)
• Inflammation (from chronic infections)a
Endurance
athletes
• Blood loss from haemolysis
• Chronic inflammationa
Elderly • Decreased intake (malnutrition)
• Gastrointestinal blood loss (benign or
malignant conditions, drug-induced)
• Decreased absorption (atrophic
gastritis, proton-pump inhibitors)





• Chronic blood loss (dialysis, use of
anticoagulants)
• Decreased intake (malnutrition)
• Decreased absorption (proton-pump
inhibitors)
• Chronic inflammationa




• Decreased intake (malnutrition)
• Decreased absorption (oedema)
• Gastrointestinal blood loss (antiplatelet
or anticoagulant)
• Chronic inflammationa (in early more
than late stages)
Obesity • Decreased absorption (bariatric surgery,





• Decreased intake (malnutrition)
• Chronic gastrointestinal blood loss







The list includes the most commonly encountered aeti-
ologies although additional risk factors can still coexist
aContributing to iron-restricted erythropoiesis (functional
iron deficiency anaemia) from high hepcidin levels, and
decreased iron absorption in the long term (absolute iron
deficiency anaemia).
bContributing to iron-restricted erythropoiesis (functional
iron deficiency anaemia).
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Pathophysiology
Iron homoeostasis
Iron homoeostasis is tightly controlled to avoid the
toxic effects of excess iron in the form of harmful
reactive oxygen species. Thus, the human body
evolved with no means for iron excretion (except for
those lost due to cell shedding amounting to
around 1 mg per day), with daily absorption lim-
ited to 1–2 mg to compensate for daily iron losses.
However, the body requires around 25 mg of iron
daily, mostly used for the production of haemoglo-
bin in erythrocytes. Iron is also a crucial element
for several cellular and tissue functions including
respiration, mitochondrial function, energy pro-
duction, especially in skeletal and cardiac muscles,
as well as cell proliferation and DNA repair [3, 32].
To achieve this aim, the body recycles most of the
required iron from the breakdown of senescent
erythrocytes by macrophages in the spleen to make
it available to plasma transferrin. This tight control
of iron absorption and recycling is mediated
through the hepatic hormone hepcidin, but can
be easily disturbed leading to various forms of ID
and subsequent anaemia [2, 4]. Additional recy-
cling mechanisms also exist in skeletal muscle
fibres and in hepatic macrophages (in cases of
intravascular haemolysis) [33, 34].
Adaptative mechanisms in absolute iron deficiency
Adaptive mechanisms in ID aim to optimize the
usage of iron by erythropoiesis and increase its
absorption. Hepcidin mainly functions by binding
and degradation of its receptor ferroportin on the
basolateral membrane of enterocytes and macro-
phages and thus preventing iron export from these
cells into the plasma [35]. In absolute ID, hepcidin
is suppressed, leading to both increased iron
absorption from the gut and release of recycled
iron from splenic macrophages into the circulation
[35]. Hepcidin suppression is triggered by
decreases in levels of iron-bound transferrin (li-
gand of transferrin receptor, noting that non-iron-
bound apotransferrin is increased) and hepatic
iron stores (unknown mechanism) which lead to
increased activity of the inhibitor transmembrane
protease serine 6 (TMPRSS6 or matriptase-2) and
reduction in the levels of the activator bone mor-
phogenetic protein 6 (BMP6) [2, 36]. Epigenetic
factors such as histone deacetylase HDAC3 erase
activation markers from the hepcidin locus which
also contributes to hepcidin suppression.[37]
Additionally, tissue hypoxia in IDA increases levels
of hypoxia-inducible factor 2a (HIF-2a) which
stimulates erythropoietin production by the kidney
leading to the expansion of erythropoiesis and
release of hypochromic, microcytic erythrocytes.
This increase in erythropoiesis during anaemia
further suppresses hepcidin through the erythroid
factor erythroferrone (ERFE), released by erythrob-
lasts [38]. HIF-2a also increases the expression of
the duodenal divalent metal transporter 1 (DMT1)
and duodenal cytochrome B (DCYTB) on the apical
surface of enterocytes, thus increasing iron
absorption from the gut lumen [39]. A role for
erythrocyte ferroportin in maintaining plasma iron
levels has also been recently reported [40]. Once
stores are depleted (macrophages followed by hep-
atocytes), plasma iron levels decrease since iron
absorption cannot meet the demand. The recycling
of iron from hypochromic erythrocytes in macro-
phages also decreases in parallel with the severity
of ID. Uptake of iron through transferrin receptors
is subsequently decreased across all body tissues.
Mechanisms in chronic inflammatory conditions
In conditions associated with chronic inflamma-
tion, the mechanism of anaemia is more complex.
Chronic inflammation, per se, can lead to a mod-
erate anaemia through several iron-unrelated
mechanisms mediated by proinflammatory cytoki-
nes – this is called anaemia of chronic disease or
anaemia of inflammation which usually resolves
when the underlying cause is treated [3, 41, 42].
Chronic inflammation has also been linked to iron
dysregulation in recent years [41]. The cytokines
interleukin (IL)-6, IL1b and IL-22 were shown to
increase hepcidin expression leading to ferroportin
degradation and sequestration of iron away from
the circulation in intestinal enterocytes (eventually
being lost through shedding) and macrophages.
Stimulation of Toll-like receptors 2 and 6 in
chronic inflammation also reduces ferroportin
expression in macrophages by hepcidin-indepen-
dent mechanisms [43]. This makes iron less avail-
able for use by body tissues in view of lower
amounts of plasma iron bound to transferrin and
leads to a state of iron-restricted erythropoiesis
and anaemia in the presence of normal or
increased iron stores [6, 12, 17, 29]. As mentioned
earlier, in the long-term, this also leads to absolute
ID in view of decreased iron absorption [3]. It
should be noted that in a recent study, mild acute
inflammation did not increase serum hepcidin in
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women with IDA, suggesting low iron status and
erythropoietic drive offset the inflammatory stimu-
lus on hepcidin expression [44].
Epidemiology
Anaemia affects one-third of the world population
with IDA being the top cause [11, 45]. IDA is highly
prevalent in preschool children (<5 years), women
in the reproductive age and pregnant women with
prevalence rates, reaching up to 41.7%, 32.8% and
40.1%, respectively (2016 Global Health Observa-
tory data) [45]. Reliance on a vegan diet, malab-
sorption syndromes and heavy menstrual bleeding
are also high-risk categories in high-income coun-
tries, with around two-third of women with heavy
menstrual bleeding having ID/IDA [2, 11, 46]. IDA
is more difficult to treat in the elderly population
and only represents around 30% of anaemia cases,
as other types of anaemia may exist [47]. Frequent
blood donation is also a poorly recognized cause of
IDA. In one study of 2425 individuals, 16.4% and
48.7% of frequent male donors showed the
absence of iron stores and iron-restricted erythro-
poiesis, respectively, with the corresponding pro-
portions of 27.1 and 66.1% for females [48].
Although formal estimates on the prevalence of
genetic forms of IDA are lacking, IRIDA is thought
to represent less than 1% of the cases of IDA seen
in medical practice [2].
The reported prevalence of ID/IDA in chronic
inflammatory conditions varies greatly amongst
different studies, depending on the thresholds of
iron parameters used to define ID. ID affects
anywhere between 37% and 61% of patients with
chronic heart failure [49–53] and between 24% and
85% of patients with chronic kidney disease [54,
55] – higher rates being associated with advanced
disease. It is also documented in 13–90% of
patients with inflammatory bowel disease depend-
ing on disease activity and severity, and whether
measured in the outpatient or inpatient setting
[54]. ID and IDA have also been reported in 42.6%
and 33% of cancer patients, respectively, and
associated with advanced disease, close proximity
to cancer therapy and poor performance status in
patients with solid tumours [56]. In the surgical
setting, preoperative anaemia is present in around
one-third of patients undergoing major surgery
with over two-third of cases having IDA. ID is also
observed in over half of surgical patients without
anaemia [57, 58]. The prevalence of postoperative
anaemia can reach up to 90% [59].
Taken together, these data alert to alarming figures
of IDA prevalence across high-risk populations,
further highlighting the importance of early detec-
tion and management in view of the negative
clinical implications.
Clinical Implications
IDA usually develops slowly from the progression of
ID. The full range of symptoms and signs associ-
ated with IDA at presentation and follow-up are
reviewed elsewhere [5, 60], whilst certain clinical
consequences are described in this section and
Fig. 2. It should be noted, however, that due to
nonspecificity of symptoms and the cooccurrence
of IDA with multiple morbidities, confounding
effects of underlying diseases on the observed
association between IDA and outcomes cannot be
fully dismissed.
IDA is associated with decreased cognitive perfor-
mance and delayed motor and cognitive develop-
ment in children, decreased physical performance
and quality of life in adults, especially women in
the reproductive age group, and cognitive decline
in the elderly [61–63]. Although these symptoms
remain nonspecific, they can be attributed to low
delivery of oxygen to body tissues in IDA. They may
also occur as a direct effect of ID [64–67], probably
due to reduced iron levels in muscle or brain
tissue, and impact on energy production, myo-
globin synthesis and brain development. Addi-
tional effects of ID attributed to the impact of low
iron levels on DNA replication and cell cycle (oral
lesions, hair loss, nail abnormalities), immune
response (increased susceptibility to infections),
myelogenesis and neurotransmission (restless leg
syndrome) and inhibition of cytochrome P450
production (altered drug metabolism) are reviewed
elsewhere [68].
Women and pregnancy
In women with heavy menstrual bleeding, IDA is
associated with reduced quality of life and general
well-being, and severe anaemia may lead to hospi-
talization [69, 70]. More importantly, it results in
many women entering pregnancy with anaemia. In
pregnant women, IDA is associated with an
increased risk of preterm labour, low neonatal
weight and perinatal complications [69]. Severe
IDA is also associated with increased newborn and
maternal mortality, due to lower tolerance to
excessive blood loss during delivery and increased
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risk of infections [71, 72]. Infants born to anaemic
mothers are more likely to have IDA themselves
[73]. ID also carries a negative impact on the
mother–child relationship and the child’s cognitive
development, an effect measurable for up to
10 years despite iron repletion [74].
Chronic inflammatory conditions
In patients with chronic inflammatory conditions,
the impact of IDA can be severe leading to disease
exacerbation and deterioration. This is particularly
relevant in elderly patients with multiple morbidi-
ties, when even mild anaemia can be associated
with increased mortality [75].
IDA is a negative prognostic factor in chronic
heart failure associated with disease progression,
decreased quality of life and an increase in
cardiovascular mortality [76, 77]. ID without
anaemia has also been associated with increased
fatigue, reduced exercise intolerance, diminished
quality of life, increased hospitalization rates and
reduced survival as compared with patients with-
out ID or those who receive iron replenishment
[20, 31, 49, 51, 52, 78–81]. This is supported by
animal studies which show that ID in heart
muscles, irrespective of systemic iron levels, is
associated with decreased heart contraction, ven-
tricle dilation and heart failure, which can be
attributed to the decrease in iron-sulphur cluster
synthesis and mitochondrial electron transport in
response to stress [82].
In chronic kidney disease, anaemia is commonly
associated with reduced energy and diminished
quality of life [83, 84]. In predialysis patients, there
is a cumulative increase in the risk of predialysis
mortality or development of end-stage renal dis-
ease with decreasing haemoglobin levels (around
2- to 3-fold for haemoglobin values <120 vs.
>130 g L1) [85]. An association between the
increased risk of mortality and anaemia was also
observed in long-term studies irrespective of dis-
ease severity [86]. Anaemia is also recognized in the
context of the cardio-renal anaemia syndrome, and
Fig. 2 Clinical implications of iron deficiency anaemia. CHF, chronic heart failure; CKD, chronic kidney disease; IBD,
inflammatory bowel disease; QoL, quality of life.
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is associated with a two-fold higher rate of cardio-
vascular hospitalization [87].
Iron deficiency anaemia is the most common extra-
intestinal manifestation in inflammatory bowel
disease and may affect the quality of life in the
same magnitude of other underlying disease-re-
lated symptoms such as abdominal pain and
diarrhoea [88]. In fact, one study showed changes
in haemoglobin level are more likely to affect the
quality of life than the underlying disease activity
[89].
Surgical setting
Preoperative anaemia, even to mild degrees, is
associated with an increased likelihood of morbid-
ity and mortality in the 30-day postoperative period
after major surgery [58, 59, 90]. It is also associ-
ated with a longer duration of hospitalization and a
higher rate of readmissions [59]. These effects have
been attributed to the direct effect of anaemia and
hypoxia, as well as to the increased risk of periop-
erative transfusions which themselves are inde-
pendently associated with an increased risk of
postoperative morbidity and mortality [91]. Post-
operative anaemia has also been associated with
infection, poor physical function and recovery,
subsequent increases in the length of stay in
hospital and mortality [59, 92]. Although studies
in the surgical setting did not commonly qualify the
type of anaemia, the high prevalence of IDA sug-
gests that it may be the main culprit [59].
DIAGNOSIS
General considerations
Three key questions need to be asked when con-
sidering the diagnosis of IDA: who should be
tested, what tests should be used and what
sequence and what laboratory thresholds deter-
mine if a patient has IDA?
Since IDA remains the most common cause of
anaemia, it should be prioritized in the diagnostic
workup of patients presenting with anaemia unless
other mechanisms are suspected to be more preva-
lent in a specific patient. Physicians may need to
actively ask high-risk patients about symptoms or
signs suggestive of IDA; however, since those may
be nonspecific, silent or overlooked, testing
patients with certain profiles or underlying diseases
known to have high prevalence of IDA, have an
established association between IDA and adverse
outcomes, and have robust evidence on the clinical
benefit of iron treatment from clinical trials may be
warranted. This ismostly relevant in patients where
multiple causes of IDA may coexist such as in older
patients with chronic inflammatory conditions [20,
47]. It is also applicable in the perioperative setting
for patients undergoing major surgery [59, 92]. In
young children, studies evaluating screening pro-
grammes have found problems with implementa-
tion, acceptability and follow-up of testing, and
most international authorities do not support this
practice. A recent US Preventive Services Task
Force recommendation statement concluded that
the current evidence base was insufficient to deter-
mine the overall net benefit of screening for IDA in
asymptomatic children aged 6–24 months. This
may not be applicable to infants with additional
known risk factors (prematurity) or with symptoms
of anaemia [93, 94]. The US Preventive Services
Task Force also does not recommend screening in
asymptomatic pregnant women; however, common
practice and expert opinion continue to suggest
routine screening for IDA in pregnant women
starting the first trimester [69, 71, 93–96]. Diag-
nostic workup should be done for both anaemia
and ID simultaneously. When IDA is diagnosed, the
continued search for additional causes of anaemia
may be necessary in patients with multiple mech-
anisms of anaemia such as the elderly, chronic
inflammatory conditions or patients with malnutri-
tion [20, 47]. Evaluation of the cause(s) of IDA is
warranted since if it can be actively treated, it will
aid in the resolution of IDA beyond iron therapy [2,
5]. Of course, if the diagnostic workup reveals
anaemia but no ID, further assessment of alternate
causes should be made to establish the optimal
course of therapy. However, in high-risk groups
such as infants, preschool children, growing ado-
lescents, young females and pregnant women,
extensive diagnostic workup is not needed consid-
ering the cause of IDA is often physiologic in view of
increased iron demand or loss and may be limited
to instances of lack of response to therapy. In
patients determined to be eligible for diagnostic
evaluation but show no laboratory evidence of IDA,
reassessment can be done at subsequent visits
depending on the underlying condition and its
activity. Figure 3 provides an algorithm for the
diagnostic workup of IDA. Detailed diagnostic
workups in specific clinical settings and popula-
tions such as women’s health and pregnancy [69,
71, 95], elderly [21, 22], children [54], chronic
inflammatory conditions [20] and perioperatively
[59, 92] have been reviewed elsewhere.
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Laboratory tests and thresholds
The diagnosis of IDA can be readily made by
assessing haemoglobin and serum ferritin levels.
According to the World Health Organization (WHO),
anaemia is defined as a haemoglobin level
<130 g L1 in men, <120 g L1 in nonpregnant
women and <110 g L1 in pregnancy [97]. Specific
thresholds at various stages of childhood are also
commonly used (Fig. 3) [97]. Further categorization
within the various stages of pregnancy is provided
by the Centres for Disease Control and Prevention
(CDC): first and third trimesters <110 g L1, sec-
ond trimester <105 g L1 and postpartum
<120 g L1 [98]. That said, it is worth noting that
a recent WHO technical meeting concluded that
there are minimal data to support haemoglobin
thresholds to define anaemia. Future directions in
assigning more evidence-based thresholds could
have considerable implications on disease defini-
tion, epidemiology and management [99]. Serum
ferritin level is the most specific and effective test to
reflect total body iron stores and is universally
available and standardized [4]. Although a value
<12–15 lg L1 is confirmatory for ID, a value of
<30 lg L 1has higher sensitivity (92%) and similar
specificity (98%) and is more widely used [5, 100],
[5, 100]. Although widely implemented and cited,
these cutoffs are based on qualitative expert opin-
ion and not a systematic appraisal of the published
work. Several projects are being coordinated by the
WHO and CDC to address this evidence gap; until
then, clinicians can rely on laboratory standards at
their centre and local guidelines [101]. In the
presence of inflammation, interpretation of serum
ferritin level is more challenging. First, ferritin, in
the form of apoferritin, is an acute-phase reactant
that increases in inflammation. Second and as
explained earlier, in chronic inflammatory condi-
tions the increase in hepcidin levels leads to iron
sequestration in macrophages. This is reflected
with normal or even high serum ferritin levels
despite decreased availability of iron in the circu-
lation. Although this has created considerable
variability in recommended serum ferritin thresh-
olds for the diagnosis of ID during inflammation
between guidelines (<50, <100 or <200 lg L1) [20,
54, 59, 69, 92], a recent international expert
consensus recommended using serum ferritin
levels <100 lg L1 to diagnose ID in chronic
inflammatory conditions [20], and the threshold
is also commonly recommended in the elderly and
postoperatively [4, 92]. Additionally, during inflam-
mation serum iron is still reduced and total iron-
binding capacity is increased despite normal or
high iron stores (functional ID), which leads to a
substantial reduction in transferrin saturation
(ratio of serum iron to total iron-binding capacity).
A transferrin saturation <16% is commonly used to
diagnose ID in general and a threshold of <20% is
proposed in the presence of inflammation [5, 20].
Thus, a practical approach during inflammation
would be to consider serum ferritin <100 lg L1 as
diagnostic whilst for patients with values of 100–
300 lg L1 to check transferrin saturation and
diagnose ID in those with values <20%. Although
this sequential approach is probably more costly, it
may be more practical to test for serum ferritin and
transferrin saturation at the same time to avoid
repeated blood withdrawals and laboratory visits.
Although identifying a state of inflammation is
straight forward in chronic inflammatory condi-
tions or postoperatively, for example, confirmation
through evaluation of markers of inflammation
may be needed in equivocal scenarios or when the
intention is to wait for acute inflammation to
resolve before relying on iron values. A C-reactive
protein value of >5 mg L1 is commonly used in the
setting of acute inflammation, although not widely
standardized [20, 54, 59, 69, 92]. Alpha glycopro-
tein (AGP) may also be used as an indicator of
chronic inflammation [102].
Other laboratory tests
In IDA, red cells are microcytic and hypochromic,
as shown by low mean corpuscular volume (MCV)
and mean corpuscular haemoglobin (MCH) and
increased red blood cell distribution width (RDW).
However, changes in red cell indices occur late in
the course of IDA in view of the red cell lifespan,
and the usefulness of these tests may be limited.
Fig. 3 Diagnostic workup for IDA. *Although widely implemented and cited, these cutoffs are based on qualitative expert
opinion and not a systematic appraisal of the published work. Several projects are being coordinated by the WHO and CDC
to address this evidence gap; until then, clinicians can rely on laboratory standards at their centre and local guidelines.
CHF, chronic heart failure; CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agents; IBD, inflammatory bowel
disease; ID, iron deficiency; IDA, iron deficiency anaemia; NYHA, New York Heart Association; Q, every; TSAT, transferrin
saturation.
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Reticulocyte haemoglobin content (RHC) indicates
the amount of iron available for erythropoiesis in
the previous 3–4 days and is an early index of ID;
the rapidity of changes makes it a potentially
useful marker to identify responders to iron sup-
plementation. The percentage of hypochromic red
cells (% HRC) also reflects recent iron reduction,
yet the value of these tests in long-standing IDA is
limited and they are not extensively used in clinical
practice for the diagnosis of IDA [3].
Serum soluble transferrin receptor (sTFRC) levels
are increased in ID (and normal/low in inflamma-
tion). A meta-analysis showed a high sensitivity
(86%) and specificity (75%) for sTFRC in the
diagnosis of ID, but this remained lower than that
of serum ferritin [103]. The ratio between sTFRC
and log ferritin (sTFRC–ferritin index) may help in
recognizing IDA in the setting of chronic inflam-
mation, although lack of standardization between
available assays limits wide use in clinical practice
[41].
Hepcidin level is decreased/undetectable in IDA,
but it is affected by several factors including
circadian rhythm, hepatic and renal function [3].
Hepcidin assessment may be useful to confirm
IRIDA, because levels are constitutionally high or
normal [18]. Few studies also suggested that high
hepcidin levels may be useful in predicting
response to oral iron supplementation [104, 105].
Although a good correlation between different
methods of hepcidin level assessment is observed
[106], it is still not routinely or widely used in
clinical practice.
In patients with IRIDA, typical findings include a
striking microcytosis and extremely low transferrin
saturation in the presence of normal or borderline
low serum ferritin levels [4].
MANAGEMENT
Prevention
Efforts to increase access to and consumption of
iron-rich foods should always be in place. Iron
absorption enhancers (ascorbic acid) or inhibitors
(calcium, phytates [cereals], tannins [tea and
coffee]) should also be considered when supplying
iron-rich meals. Enrichment of food (rice, maize
flour, cornmeal) with iron is also practiced in some
countries, such as in Asia, Africa and Latin
America, and recommended by the WHO [5, 107,
108]. The WHO recommends iron
supplementation to prevent ID/IDA in instances
where the prevalence of anaemia is 40% or higher:
children 6–23 months (10–12.5 mg elemental iron
daily – drops/syrups, three consecutive months in
a year), 24–59 months (30 mg elemental iron daily
– drops/syrups/tablets, three consecutive months
in a year), 5–12 years (30–60 mg elemental iron
daily – tablets/capsules, three consecutive
months in a year). In malaria-endemic areas, the
provision of iron supplementation in infants and
children should be done in conjunction with
public health measures to prevent, diagnose and
treat malaria [109]. Although iron repletion can
reverse the protective effect of ID on malaria
infection, it is less of a concern in areas where
preventive services are provided [110, 111]. The
WHO also recommends iron supplementation in
the same setting for menstruating adult women
and adolescent girls (nonpregnant females in the
reproductive age group) with 30–60 mg elemental
iron daily tablets for three consecutive months in
a year [112].
Iron supplementation for iron deficiency anaemia
General considerations
Management of the underlying cause of IDA should
always be considered. For example, treating H. py-
lori infection or introduction of gluten in coeliac
disease can restore iron absorption [8, 113]. Inves-
tigation and management of the source of gastroin-
testinal blood loss are also warranted in men and
postmenopausal women. These measures not only
prevent further iron loss or improve iron absorp-
tion, but also aid in prompt diagnosis of potentially
serious underlying diseases.
An important question in IDA management is
whether oral or intravenous iron therapy should
be used. Comparison of both modes of adminis-
tration is summarized in Table 2 [20]. Generally
speaking, factors that should be considered in
decision making include patients’ age and sex,
the underlying condition and cause of IDA, the
severity of anaemia or ID and their symptoms,
and the time frame available or acceptable for
correction. Intravenous therapy can be generally
considered when response, tolerability or adher-
ence to oral iron therapy are not ideal or when
anaemia or ID is severe. Unless contraindicated,
oral iron therapy can be started and patient
evaluated with haemoglobin and iron indices;
the frequency of monitoring and duration of
therapy should rely on the underlying condition
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and specific treatment goals. In cases of intoler-
ance or when signs of nonresponse are noted
despite efforts to improve tolerance (low or alter-
nate day dosing, use of newer oral formulations
[4, 114, 115]), adherence (modification of dose
and frequency) or absorption (eradication of
H. pylori infection or introduction of gluten-free
diet in coeliac disease), intravenous iron can be
considered with appropriate dosing. Continued
monitoring of haemoglobin and iron status every
1–3 months should be ensured until normaliza-
tion of laboratory values; whilst further investi-
gation for alternate causes of anaemia is
warranted in case of nonresponse [5]. More
specific indications for intravenous iron therapy
are summarized in Table 3 and relevant data is
further discussed in this section. Six intravenous
iron formulations are available: ferric gluconate,
iron sucrose, low-molecular-weight iron dextran,
ferumoxytol ferric carboxymaltose and iron iso-
maltoside. Details of various formulations, their
dosing and pivotal data on efficacy, safety and
adverse event management are reviewed else-
where [2, 4, 5, 116, 117], but use should follow
local guidelines and product prescribing informa-
tion.
Pregnancy
In pregnant women with IDA, recent guidelines
recommend use of intravenous iron in the second
trimester if haemoglobin level is <105 g L1 and
anytime in the third trimester [71]. Earlier studies
indicated comparative effects of intravenous and
oral iron in pregnant women, with respect to
haematologic, maternal and foetal outcomes
[118]. More recent trials, however, showed the
superiority of intravenous over oral iron during
pregnancy [119, 120]. A single dose of intravenous
iron was also more effective than oral iron in
improving fatigue after postpartum haemorrhage,
and was as effective as blood transfusions in
management of severe anaemia; although the latter
would be needed in cases of haemodynamic insta-
bility [121, 122]. Risk-benefit and cost-effective-
ness considerations should always be taken into
consideration before the decision to use intra-
venous iron therapy is made, especially in
resource-poor countries.




• Ingested iron absorption is low (10–
20%)• Reduced in inflammation
conditions
• Not affected by inflammation
Administration
ease
• Easy • Requires expertise and facility for cardiopulmonary
resuscitation• Administration site reactions•Potentially
fatal hypersensitivity reactions (especially iron dextran)•
Recurrent dosing
Dosing • Daily up to three times per day • Single high-dose or multiple
Response • Can be limited • Higher efficiency and shorter duration to improve
haemoglobin levels and iron indices
Gastrointestinal
side effects




• Skin discoloration • Headache and joint pain• Hypophosphataemia and
osteomalacia with some formulations
Adherence • Lower • Higher
Cost • Lower • Higher
Overdose • Accidental overdose possible with
ferrous salts
• Variable complex stability, can induce oxidative stress at
high doses
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Chronic inflammatory conditions
In patients with chronic inflammatory conditions,
response to oral iron therapy may be limited by the
hepcidin-mediated decreased absorption. In iron-
deficient patients with heart failure and reduced
ejection fraction, high-dose oral iron did not
improve exercise capacity over 4 months [123]. In
placebo-controlled trials, intravenous iron therapy
significantly improved symptoms, functional
capacity and quality of life in patients with chronic
heart failure [New York Heart Association (NYHA)
class II or III] and ID, irrespective of the presence of
anaemia [77, 124]. A reduction in hospitalization
rate by up to 61% was also observed in other trials
[125]. A recent meta-analysis of randomized trials
concluded that intravenous iron therapy in
patients with systolic heart failure and ID improves
outcomes, exercise capacity and quality of life, and
alleviates heart failure symptoms [126]. This has
led to wide recommendation of compulsory screen-
ing and intravenous iron treatment in chronic
heart failure patients even in the absence of
anaemia [20]. It should be noted, however, that
the previously mentioned thresholds to define ID
(using ferritin and TSAT) which are also commonly
used in these trials have rarely been prospectively
validated [127].
In inflammatory bowel disease, gastrointestinal
side effects, increased local inflammation from iron
and alterations in gut microbiota can mitigate the
use of oral iron therapy [128]. Laboratory or
imaging studies may be needed to determine dis-
ease activity and decide on the choice of oral or
intravenous iron therapy. In patients with active or
advanced disease or those with haemoglobin val-
ues ≤100 g L1, intravenous iron is recommended
over oral iron for the management of IDA [20, 129].
Unfortunately, the need for iron replenishment in
these patients is poorly recognized with one study
showing that over 50% of patients with inflamma-
tory bowel disease and IDA did not receive treat-
ment [130].
In patients with chronic kidney disease, oral or
intravenous iron may be used, although data from
clinical trials show better haemoglobin response
in patients with IDA who took intravenous com-
pared with oral iron [131]. Normalization of
haemoglobin levels is associated with significant
physical function improvement, but the effect on
the risk of cardiovascular events is not clear.[111]
Intravenous iron is recommended front line in
patients on dialysis [20]. A recent trial showed
that in patients undergoing haemodialysis, proac-
tive administration of high-dose intravenous iron
is superior to reactive administration (triggered by
a diagnosis of ID) of a low-dose regimen and
resulted in lower doses of ESA being used [132].
ESA therapy is not always associated with clinical
benefit in patients with chronic kidney disease,
and anaemia and may be associated with
increased risk of stroke [133]. When administered,
ESA therapy should always follow iron treatment
since it may worsen ID, and in this setting
intravenous iron is more effective than oral iron
[20]. Iron therapy may also delay or abolish the
need for ESA in the first place [19]. In cancer
patients, iron therapy is recommended for IDA or
following a lack of response to ESA [19]. An
increased risk of infection with the use of intra-
venous iron, especially in haemodialysis patients,
has been a subject of debate. A recent meta-
analysis concluded that high-dose parenteral iron
does not seem to be associated with higher risk of
infection or all-cause mortality on analysis of
randomized trials. Observational studies show
increased risk for all-cause mortality, infections
and hospitalizations that were not statistically
significant and were associated with significant
heterogeneity [134].
Table 3. Indications when intravenous iron therapy should
be considered
Indication
Intolerance, nonresponse, poor adherence to oral iron
Rapid or significant correction of anaemia and/or iron
deficiency needed
Medical and surgical conditions with decreased
absorption (cause cannot be treated)
Iron-refractory iron deficiency anaemia (IRIDA)
Chronic heart disease (systolic, NYHA class II–IV)
Chronic kidney disease (dialysis, or with ESA
treatment)
Inflammatory bowel disease (active disease or
haemoglobin <100 g L1)
Preoperatively (surgery scheduled in <6 weeks)
Postoperatively
Pregnancy (second trimester if haemoglobin <105 g L1
and third trimester)
ESA, erythropoiesis-stimulating agents; NYHA, New York
Heart Association.
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Cancer
Iron administration to anaemic cancer patients can
increase the level of haemoglobin probably inde-
pendently from the specific mechanism of anae-
mia, which may help reduce the need for blood
transfusions and ESA therapy [135]. There is a lack
of consensus on the specific indication for iron
supplementation, although most guidelines rec-
ommend use when ID is documented, and a
preference towards intravenous iron therapy espe-
cially in cases of functional IDA or with planned
use of ESA [136, 137].
Surgical setting
In surgical patients, the concept of patient blood
management is widely recognized [138], and relies
on the idea of early detection of anaemia and
management prior to major surgical procedures to
avoid the need for blood transfusions periopera-
tively, the latter being strictly reserved to patients
with severe anaemia and haemodynamic instabil-
ity. The consensus is that IDA needs to be
identified and treated as soon as the decision to
perform an elective surgery is taken, otherwise,
surgery may be delayed if possible until IDA is
effectively managed. International guidelines rec-
ommend that preoperative IDA can be treated with
oral iron therapy, whilst intravenous iron can be
used in case of nonresponse or intolerance, or
front line if surgery is scheduled within less than
six weeks [59]. Recent data from clinical trials,
however, show superiority of intravenous over oral
iron in improving haemoglobin level and iron
indices [139], and effectiveness of intravenous
iron in decreasing the duration of hospital stay,
postoperative anaemia and need for blood trans-
fusions [140–142]. Safety was also established in
such trials. This may suggest that the use of
intravenous iron in the preoperative setting could
be prioritized, not only when the time available for
correction of IDA is short, but also in patients
with severe IDA or patients that are known to be
less responsive to oral therapy such as older
patients with chronic inflammatory conditions. In
the postoperative period, early intravenous iron
therapy is recommended as a single high dose
unless otherwise contraindicated, especially in
view of postoperative inflammation [92]. In
patients with IDA, intravenous iron therapy was
associated with improvement of anaemia and ID,
fewer blood transfusions and lower risk of severe
infections in the four weeks following surgery
[143, 144].
Conclusion
Iron deficiency anaemia is a significant public
health concern that can cause debilitating clinical
consequences across age groups, genders, geogra-
phies and clinical conditions. Early diagnosis and
effective management are thus needed to avoid
associated sequelae. This can only be achieved
with increased awareness of the prevalence and
causes of IDA, as well as the benefits of treatment,
amongst healthcare professionals. Although effec-
tive means for iron supplementation exist, making
the right and timely choice between oral and
intravenous iron formulations is essential to avoid
unnecessary delays in iron repletion and correction
of anaemia. The development of new oral iron
formulations with fewer gastrointestinal side
effects may result in more patients receiving and
tolerating therapy. Moreover, many studies of
intravenous iron have limited follow-up duration
or small sample sizes, and large, randomized trials
with standardized end points are needed to better
establish the role of intravenous therapy across
indications. Ongoing research aiming to better
understand iron metabolism and the role of hep-
cidin as a diagnostic tool and treatment target
could bring more novel diagnostic and therapeutic
interventions in future years.
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